Graft Versus Host Disease (GVHD) Therapeutics Pipeline Report, H1 2017: Review of 61 Companies & Their Drug Profiles - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2017" report to their offering.

Pharmaceutical and Healthcare latest pipeline guide Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (GVHD) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Graft Versus Host Disease (GVHD) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Graft Versus Host Disease (GVHD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 7, 23, 11, 35, 7 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 3, 13 and 2 molecules, respectively.

Graft Versus Host Disease (GVHD) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Graft Versus Host Disease (GVHD) - Overview
  3. Graft Versus Host Disease (GVHD) - Therapeutics Development
  4. Graft Versus Host Disease (GVHD) - Therapeutics Assessment
  5. Graft Versus Host Disease (GVHD) - Companies Involved in Therapeutics Development
  6. Graft Versus Host Disease (GVHD) - Drug Profiles
  7. Graft Versus Host Disease (GVHD) - Dormant Projects
  8. Graft Versus Host Disease (GVHD) - Discontinued Products
  9. Graft Versus Host Disease (GVHD) - Product Development Milestones
  10. Appendix

Companies Mentioned

- AbbVie Inc

- AbGenomics International Inc

- Allergan Plc

- Amunix Operating Inc

- AnaptysBio Inc

- apceth Biopharma GmbH

- Aptevo Therapeutics Inc

- arGEN-X BV

- Athersys Inc

- Bellicum Pharmaceuticals Inc

- Bio-Cancer Treatment International Ltd

- Biogen Inc

- Bristol-Myers Squibb Company

- Capricor Therapeutics Inc

- Cell2B Advanced Therapeutics SA

- CellECT Bio Inc

- Commence Bio Inc

- Cynata Therapeutics Ltd

- Cytodyn Inc

- Dr. Falk Pharma GmbH

- Escape Therapeutics Inc

- F. Hoffmann-La Roche Ltd

- Fate Therapeutics Inc

- Generon (Shanghai) Corp Ltd

- Gilead Sciences Inc

- GlaxoSmithKline Plc

- Incyte Corp

- Jazz Pharmaceuticals Plc

- Kadmon Corp LLC

- Kamada Ltd

- Kiadis Pharma NV

- Kymab Ltd

- Kyorin Pharmaceutical Co Ltd

- MacroGenics Inc

- Mallinckrodt Plc

For more information about this report visit http://www.researchandmarkets.com/research/85xwv5/graft_versus_host

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Immune Disorders Drugs, Immunosuppressive Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Immune Disorders Drugs, Immunosuppressive Drugs